For example, blocking sdc-3 or sdc-4 in human RA would be of potential interest in reducing inflammation and joint destruction, whereas this strategy may have opposite effects in certain inflammatory conditions of the skin, lung, gut and kidney. This evidence concerns the gene SDC3 and rheumatoid arthritis.